News

  • Aspira Women’s Health to Present at The Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference

     February 22, 2024 08:30 ET  AUSTIN, Texas, Feb. 22, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at The Cancer Advocacy Group of Louisiana’s 3rd…

  • Aspira Women’s Health Announces Late-Breaking Poster Presentation at the Upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)

     February 12, 2024 08:00 ET  AUSTIN, Texas, Feb. 12, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at the upcoming 71st Annual Scientific Meeting for the Society for Reproductive Investigation (SRI)…

  • Aspira Women’s Health Announces OvaSuite(SM) Distribution Agreement in the Philippines

     February 06, 2024 08:00 ET  Hi-Precision Laboratories, one of the largest medical laboratories in the Philippines, signs a 5-year OvaSuitSM commercial distribution agreement AUSTIN, Texas, Feb. 06, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools,…

  • Aspira Women’s Health Announces $5.5 Million Registered Direct Offering and Concurrent Private Placement

     January 25, 2024 08:00 ET  AUSTIN, Texas, Jan. 25, 2024 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor alongside…

  • Aspira Women’s Health to Host R&D Day With Updates on the Development of the Company's Ovarian Cancer and Endometriosis Tests on January 4, 2024

     December 19, 2023 08:00 ET  AUSTIN, Texas, Dec. 19, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it will host a virtual R&D day featuring experts who will present the exciting…

  • Aspira Women’s Health to Participate in Corporate Access Events During JP Morgan Healthcare Conference Week 2024

     December 14, 2023 08:00 ET  Aspira management will be available for meetings in San Francisco (January 8-10, 2024) AUSTIN, Texas, Dec. 14, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that management will be available for…

  • Aspira Women’s Health Provides a Development Update on its Portfolio of Noninvasive Tests for Endometriosis

     December 06, 2023 08:00 ET  Data supports EndoCheck™ to be the first blood test for the identification of localized endometriosis, including endometrioma Platform migration to begin on the Company’s EndoMDx™ test for broader endometriosis indications AUSTIN, Texas, Dec. 06, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused…

  • Aspira Women’s Health Secures Reimbursement for Ova1Plus(R) from California Medicaid (Medi-Cal)

    California Medicaid (Medi-Cal) added Ova1Plus(R) to its fee schedule at $897 per test  November 28, 2023 08:00 ET  AUSTIN, Texas, Nov. 28, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that California Medicaid (Medi-Cal) added…

  • Aspira Women’s Health Receives Final Crosswalk Pricing Determination from the Centers for Medicare & Medicaid Services (CMS)

     November 27, 2023 09:47 ET  CMS approves OvaWatchSM 2024 price at $897 per test AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that during the 2024 Clinical Laboratory Fee Schedule (CLFS)…

  • Aspira Women’s Health Reports Third Quarter 2023 Financial Results

     November 13, 2023 16:05 ET  Product revenue increased 9% to $2.2 million for the quarter, and 19% to $7.0 million year to date OvaSuite sales volume increased 5% to 5,783 units for the quarter, and 16% to 18,331 units year to date Third quarter cash utilization of $3.3 million, a decrease of 56% compared to…

  • Aspira Women’s Health Supports Centers for Medicare & Medicaid Services (CMS) Proposed Rule to Crosswalk Medicare Reimbursement Rate for OvaWatch

     November 09, 2023 08:00 ET  The proposed rule would allow for OvaWatchSM to be reimbursed at the same rate as Ova1® at $897 per test and will become final following a brief public comment period AUSTIN, Texas, Nov. 09, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on…

  • Aspira Women’s Health to Announce Third Quarter Earnings Results and Host a Conference Call on Monday, November 13, 2023

     October 31, 2023 08:00 ET  AUSTIN, Texas, Oct. 31, 2023 (GLOBE NEWSWIRE) —  Aspira Women’s Health Inc. (“Aspira”), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that the company will report its financial results for the three months ended September 30, 2023 on Monday,…

  • Aspira Women’s Health Sees Poster on its miRNA-based Ovarian Cancer Test Presented at the AACR Special Conference in Cancer Research

    Data showed miRNA-protein models potential to improve the diagnostic accuracy of non-invasive ovarian cancer tests  October 25, 2023 08:00 ET  AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases today announced that a…

  • Aspira Women’s Health Establishes a New Clinical Advisory Board

    Clinical Advisory Board comprised of preeminent physicians with deep clinical expertise in gynecologic health  October 23, 2023 08:00 ET  AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has established a…

  • Aspira Women’s Health to Present at the BioVenture Nexus Conference

    The conference is taking place on October 5-6, 2023, in Los Angeles, CA  September 29, 2023 08:00 ET  AUSTIN, Texas, Sept. 29, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced…

  • Aspira Women’s Health Regains Nasdaq Compliance

     September 13, 2023 08:00 ET  AUSTIN, Texas, Sept. 13, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced that it received written notice from the Nasdaq Stock Market LLC (“NASDAQ”) on September 12, 2023 informing the…

  • Aspira Women’s Health Announces Dr. Jody Berry as New Chief Scientific Officer

     September 11, 2023 08:00 ET  AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development and commercialization of women’s health diagnostic tools for gynecologic diseases, today announced it has named Jody Berry, Ph.D. as its new Chief Scientific Officer. Dr. Ryan Phan, who stepped down…

  • Aspira Women’s Health Signs Exclusive Sample Procurement Agreement with The University of Oxford

     August 31, 2023 08:00 ET  Samples to be used in validating the Company’s EndoCheckSM test in development for the diagnosis of endometriosis AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based diagnostic company focused on gynecologic health, today announced a material transfer agreement…

  • Aspira Women’s Health to Present at the H.C. Wainwright 25th Annual Global Investment Conference

     August 29, 2023 08:00 ET  AUSTIN, Texas, Aug. 29, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced that Nicole Sandford, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright…

  • Aspira Women’s Health Announces Michelle Snider as Senior Vice President, Commercial Strategy and Operations

     August 28, 2023 08:00 ET  AUSTIN, Texas, Aug. 28, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc.(“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical company focused on the development of women’s health diagnostic tools for gynecologic diseases, today announced it has named Michelle Snider as Senior Vice President, Commercial Strategy and Operations. Ms. Snider has spent her 20+ year career in women’s healthcare and diagnostics. She…

  • Aspira Women’s Health® Reports Second Quarter 2023 Financial Results

     August 14, 2023 16:01 ET  Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022. OvaSuiteSM volume of 6,289 units, an increase of 16% year-over-year Achieved cash used in operations of $3.4 million, a decrease of 46% compared to the second quarter of 2022 Conference…

  • Aspira Women’s Health Announces Transition of its Chief Scientific Officer/Chief Operating Officer

     August 09, 2023 16:05 ET  AUSTIN, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or “the Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that Ryan Phan, Ph.D., is stepping down as the Company’s Chief Scientific and Operating Officer…

  • Aspira Women’s Health to Announce Second Quarter Earnings Results and Host a Conference Call on Monday, August 14, 2023

     July 31, 2023 08:00 ET  AUSTIN, Texas, July 31, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira”), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the company will report its financial results for the three months ended June 30, 2023 on Monday, August 14,…

  • Aspira Women’s Health Announces $4.7 Million Registered Direct Offering

     July 20, 2023 08:30 ET  AUSTIN, Texas, July 20, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has entered into definitive agreements with institutional investors, alongside participation from certain longstanding…

  • Aspira Women’s Health, Inc. Received a $1 MM Loan Forgiveness and 6-Month Payment Deferral from the CT DECD

     June 28, 2023 08:00 ET  AUSTIN, Texas, June 28, 2023 (GLOBE NEWSWIRE) — Aspira Women’s Health, Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that the Connecticut Department of Economic and Community Development (“DECD”) has determined that Aspira satisfied…